Sugar-Linked Drug Conjugates for HBV Rebound and Side-Effect Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B, such as Tenofovir and Entecavir, require continuous administration and can lead to severe viral rebound if stopped, and IAP inhibitors like Birinapant cause side effects when combined with HBV drugs.
Innovation Solution
A drug conjugate comprising a hepatitis virus targeting drug or IAP antagonist linked with a sugar through specific linkers, forming a pharmaceutical composition that includes pharmaceutically acceptable excipients, administered in doses of 0.1 mg/kg to 100 mg/kg.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Tenofovir or Entecavir are used for hepatitis B treatment, then viral suppression is achieved, but severe viral rebound occurs if administration is stopped
Solution Approach 1:
The patent conjugates IAP inhibitors with hepatitis B drugs to create a combined therapeutic agent that preliminarily addresses both viral suppression and immune system support. This preliminary action aims to prevent severe viral rebound by having the IAP inhibitor component ready to counteract immune system problems that could trigger rebound, eliminating the need for continuous separate administration of multiple drugs.
Solution Approach 2:
The patent merges two separate therapeutic functions into a single conjugate molecule: the hepatitis B virus targeting function (from drugs like Tenofovir or Entecavir) and the apoptosis inhibition function (from IAP inhibitors). This merging allows both functions to work synergistically in one administered agent, reducing the complexity of continuous multi-drug administration while maintaining reliable viral suppression and preventing rebound.
2Reliability
If IAP inhibitors like Birinapant are combined with HBV drugs, then potential hepatitis B treatment benefit is achieved, but side effects such as cranial nerve palsies occur
Solution Approach 1:
The patent applies local quality by selectively targeting liver cells through the IAP inhibitor component while the hepatitis B drug component targets the virus. This localized action in the liver may reduce systemic side effects like cranial nerve palsies that occur with non-specific systemic administration of IAP inhibitors alone, while maintaining treatment efficacy.
Solution Approach 2:
The conjugate structure acts as an intermediary that delivers the IAP inhibitor specifically to liver cells infected with hepatitis B virus. This targeted delivery mechanism reduces exposure of other tissues (including cranial nerves) to the IAP inhibitor, thereby reducing side effects while maintaining the therapeutic benefit in the liver.
3Quantity of substance
If conventional hepatitis B drugs are administered continuously, then viral load is suppressed, but immune system problems can still cause severe acute exacerbation
Solution Approach 1:
The patent creates a multi-functional conjugate that simultaneously performs viral suppression (through the hepatitis B drug component) and immune system support (through the IAP inhibitor component). This universality allows a single agent to address both viral load control and protection against immune-mediated acute exacerbation, which conventional single-function drugs cannot achieve alone.
Data Source
AI summary
A drug conjugate includes a structure shown by the following formula: Z-(linker-[R]m)n. In the formula, Z is a drug compound, R is a sugar, and m and n are independently an integer from 1 to 6. The drug compound Z is a hepatitis virus targeting drug, a hepatitis B virus (HBV) drug, an inhibitor of apoptosis protein (IAP) antagonist, a multidrug resistance (MDR) inhibitor, or analogues, precursors, prodrugs, derivatives thereof.